Anne Wojcicki’s nonprofit, TTAM Research Institute, has won a bid to acquire 23andMe for $305 million after the genetic testing company filed for bankruptcy in March. This marks the final twist in the bidding war between TTAM and Regeneron Pharmaceuticals, which had previously announced its intention to buy most of 23andMe’s assets for $256 million.
Wojcicki stepped down from 23andMe on the day it filed for Chapter 11 bankruptcy, amidst concerns over data privacy. The company’s struggles drew attention in September last year when all seven independent directors resigned en masse, citing frustration with Wojcicki’s leadership.
In November, 23andMe cut about 40% of its workforce and discontinued research into therapies, as part of a restructuring effort. The company had once been valued at $6 billion, but had struggled to convert one-time buyers into subscribers.
The acquisition has raised concerns over data privacy, with 27 states and the District of Columbia filing a lawsuit against 23andMe to block the sale of genetic data without customer consent. TTAM has promised to comply with 23andMe’s existing policies regarding customer data rights.
Wojcicki has stated that she is “thrilled” about the acquisition, which will allow her nonprofit to continue the mission of 23andMe to help people access and benefit from their genetic data. The deal still needs to be approved by the US Bankruptcy Court for the Eastern District of Missouri, with a hearing scheduled for June 17.
Source: https://edition.cnn.com/2025/06/14/business/23andme-wojcicki-dna-data